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Beta Interferons (IFN-βs) represent one 
of the first line treatments for relapsing-
remitting multiple sclerosis (RRMS), slowing 
disease progression whilst reducing the 
frequency of relapses. Despite this, more 
effective, well tolerated therapeutic strategies 
are needed. Cannabinoids palliate experimental 
autoimmune encephalomyelitis (EAE) 
symptoms and have therapeutic potential in MS 
patients although the precise molecular 
mechanism for these effects is not understood. 
Toll-like receptor (TLR) signaling controls 
innate immune responses and TLRs are 
implicated in MS. Here we demonstrate that the 
synthetic cannabinoid R(+)WIN55,212-2 is a 
novel regulator of TLR3 and TLR4 signaling by 
inhibiting the pro-inflammatory signaling axis 
triggered by TLR3 and TLR4 whilst selectively 
augmenting TLR3-induced activation of IFN 
regulatory factor 3 (IRF3) and expression of 
IFN-β. We present evidence that 
R(+)WIN55,212-2 strongly promotes the 
nuclear localization of IRF3. The potentiation 
of IFN-β expression by R(+)WIN55,212-2 is 
critical for manifesting its protective effects in 
the murine MS model EAE as evidenced by its 
reduced therapeutic efficacy in the presence of 
an anti-IFN-β antibody. R(+)WIN55,212-2 also 
induces IFN-β expression in MS patient 
peripheral blood mononuclear cells (PBMCs), 
whilst downregulating inflammatory signaling 
in these cells. These findings identify 
R(+)WIN55,212-2 as a novel regulator of TLR3 
signaling to IRF3 activation and IFN-β 
expression and highlights a new mechanism 
that may be open to exploitation in the 
development of new therapeutics for the 
treatment of  MS.  
 
IFN-β is one of several 
immunomodulatory drugs currently available to 
treat patients with RRMS (1), displaying 
significant beneficial effects on disability 
progression (2) and relapse rate (3). The 
mechanism(s) of action of IFN-β is clearly 
complex with demonstrated effects on antigen 
presentation, co-stimulatory molecule expression 
T-cell proliferation and leukocyte migration (4). 
Despite its success in the clinic, IFN-β therapy has 
demonstrated partial efficacy along with various 
side effects (4), indicating a pressing need for 
more effective strategies. 
Cannabis (Cannabis sativa) has a long 
history of consumption therapeutically (5). The 
term “cannabinoid” incorporates the active 
components of Cannabis sativa, the plant-derived 
cannabinoids, the endogenous cannabinoids 
(endocannabinoids) and the synthetic cannabinoid 
ligands. Cannabinoids are used for the 
treatment/management of inflammatory conditions 
including MS (6), arthritis (7) and glaucoma (8). 
Indeed Sativex (a combination of two plant-
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derived cannabinoids, tetrahydrocannabinol (THC) 
and cannabidiol) is currently approved for the 
neuropathic pain and spasticity associated with MS 
(9). Despite the growing clinical use of 
cannabinoids their mechanism(s) of therapeutic 
action are not fully elucidated. 
Cannabinoids elicit their effects via 
cannabinoid receptors (CB1 and CB2) (10,11). 
However, some cannabinoid-induced effects are 
mediated independently of these receptors (12). 
Cannabinoid receptors are localized throughout the 
central nervous system (CNS) (13) and on immune 
cells associated with neuroinflammation (14). This 
is particularly relevant as cannabinoids 
therapeutically impact diseases associated with a 
dysregulation of the immune and nervous systems 
(13). Indeed in EAE cannabinoids attenuate the 
development of disease (15). The roles of CB1/2 in 
mediating these effects varies depending on the 
pharmacological profile of the cannabinoid (16). 
Furthermore, whilst CB1 confers neuroprotection 
in the CNS (17), the CB2 receptor plays a pivotal 
protective role in the periphery by regulating T-
cell effector function and myeloid progenitor 
trafficking into the CNS (16,18). 
TLRs are single transmembrane receptors 
involved in the recognition of bacterial/viral 
products and induce signaling involving the 
activation of transcription factors, such as NF-κB, 
and induction of genes encoding IFNs and 
cytokines (19). To date, 13 mammalian TLRs have 
been identified, and with the exception of TLR3, 
all TLRs recruit the adaptor myeloid 
differentiation factor 88 (MyD88) (20). TLR3 (and 
TLR4) induces MyD88-independent signaling to 
regulate NF-κB via Toll-Interleukin-1 Receptor 
(TIR)-domain-containing adaptor-inducing IFN-β 
(TRIF) protein. Such TRIF-mediated signaling 
constitutes the MyD88-independent pathway and 
in addition to stimulating NF-κB, this pathway 
promotes the phosphorylation of transcription 
factors IRF3 and IRF7, via two kinases, TRAF 
family member-associated NF-κB activator 
(TANK)-binding kinase 1 (TBK1) and inducible 
IκB kinase (IKK-i) (21). The phosphorylation of 
IRF3/7 promotes their nuclear translocation and 
induction of type I IFNs (19). With respect to MS, 
specific roles of TLRs have been shown in EAE 
(22), with changes in TLR expression observed in 
MS brain lesions (23).  
 Since IL-1 signaling is sensitive to 
R(+)WIN55,212-2 (24) and the IL-1R and TLRs 
contain a homologous Toll/IL-1R (TIR) domain 
(25), we aimed to evaluate the effects of 
R(+)WIN55,212-2 on TLR signaling, with 
particular focus on the molecular mechanism 
controlling the induction of IFN-β. Protective roles 
in EAE have been demonstrated for TLR3 (26) 
and TLR4 (27) and thus we focused on the effects 
of R(+)WIN55,212-2 on these pathways. We show 
that whilst R(+)WIN55,212-2 negatively regulates 
the activation of NF-κB in response to TLR3/4, it 
enhances TLR3-induced IRF3 activation and IFN-
β expression. We further show that 
R(+)WIN55,212-2-induced expression of IFN-β 
mediates its protective effects in EAE. Finally, 
evidence is presented that the positive effects of 
R(+)WIN55,212-2 on IFN-β is apparent in cells 
from MS patients. This study thus identifies a 
novel regulatory pathway that may be open to 
exploitation in the therapeutic treatment of MS.  
 
EXPERIMENTAL PROCEDURES 
 
Cell culture - HEK293 cells stably expressing the 
TLR3 and TLR4 receptors were from InvivoGen 
(Toulouse, France). Human U373 astrocytoma cells 
stably transfected with CD14 (U373-CD14) and 
bone marrow derived macrophages (BMDMs) from 
wildtype and TRIF-deficient mice were gifts from 
Dr. Katherine Fitzgerald (University of 
Massachusetts Medical School, MA). Cell lines were 
maintained in DMEM supplemented with 10% FBS, 
100 µg/ml penicillin and 100 µg/ml streptomycin. 
Cells were maintained in a 37ºC humidified 
atmosphere with 5% CO2. The neomycin analog 
G418 (500 µg/ml) was used to select for the stably 
transfected TLR cell lines and maintenance of CD14 
expression. Primary astrocytes were prepared as 
previously described (28) from the whole brain of 1-
day old C57/BL6 mice in accordance with the 
guidelines laid down by the local ethical committee 
(National University of Ireland Maynooth). Briefly, 
astrocytes were isolated from mixed glia at day 10-
14 by removing non-adherent cells with mechanical 
shaking and harvesting by trypsinization (0.25% 
Trypsin-0.02% EDTA). Cells were centrifuged 
(2,000 X g for 5 min at 200C) and the astrocyte-
enriched pellet resuspended in DMEM. Astrocytes 
were plated (1 × 105 cells/ml) on 6- or 12-well plates 
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and treated 24 h later. R(+)WIN55,212-2 and S(-
)WIN55,212-2 (Sigma, Poole, UK) were initially 
dissolved in DMSO and stored as 5 mM stock 
solutions. For culture use, the stock drug was diluted 
to a final concentration in culture media and DMSO 
(≤0.1%) used as vehicle control. 
 
Patients and blood samples - Healthy donors and 
MS patients attending out-patient clinics at Queens 
Medical Centre University Hospital, University of 
Nottingham, UK, were recruited for this study. 
Written informed consent was obtained from each 
patient and the study received ethical approval 
from the Nottingham Research Ethics Committee. 
Patients with RRMS were clinically stable with an 
age ranging between 38-56 yrs (mean 48.4 ± 8.3; n 
= 3). Patients were naïve to any disease modifying 
therapies including IFN-β, glatiramer acetate and 
natalizumab. Healthy individuals were recruited 
from the University of Nottingham (mean age 31 ± 
2.6; n = 3). Venous blood (30 ml) was obtained 
from each subject. PBMCs were isolated using the 
Ficoll-Hypaque isolation technique and plated (1 × 
106 cells/ml) on 24-well plates.  
 
Transient transfections - HEK293 cells, U373-
CD14 cells and BMDMs (2 x 105 cells/ml) were 
seeded in 96-well plates and allowed to adhere for 
24 h. Cells were transfected using Lipofectamine 
2000 with firefly luciferase NF-κB reporter 
plasmids (κB-luc) (80 ng), constitutively expressed 
Renilla-luciferase reporter construct (phRL-TK) 
(20 ng), IFN-β luciferase reporter construct (80 
ng), positive regulatory domain (PRD)I-III 
luciferase reporter construct (80 ng) and TRIF 
reporter constructs (50 ng). To measure the 
activation of IRF3, cells were transfected with 
pFR-Luc (60 ng) and the trans-activator plasmids 
pFA-IRF3 (IRF3 fused downstream of the yeast 
Gal4 DNA binding domain, 30 ng). To measure 
the activation of IRF7, cells were transfected with 
pFR-Luc (60 ng) and the trans-activator plasmid 
pFA-IRF7 (IRF7 fused downstream of the yeast 
Gal4 DNA binding domain, 25 ng). Cells were 
allowed to recover overnight and then pre-treated 
with or without R(+)WIN55,212-2 or S(-)WIN 
55,212-2 for 1 h prior to stimulation in the 
presence or absence of the TLR4 agonist, LPS 
(100 ng/ml; Alexis Corporation, Lausen, 
Switzerland) or the TLR3 ligand, Poly(I:C) (25 
µg/ml; InvivoGen) for a further 4-6 h. Cell extracts 
were generated using the Reporter lysis buffer 
(Promega, Southampton, UK) and extracts assayed 
for firefly luciferase and Renilla-luciferase activity 
using the Luciferase assay system (Promega) and 
coelenterazine (1 µg/ml), respectively. 
Luminescence was monitored with a Glomax 
microplate luminometer (Promega). The Renilla 
luciferase plasmid was used to normalize for 
transfection efficiency in all experiments. 
 
Induction and assessment of EAE - EAE was 
induced in mice as described (29). Female SJL/J 
mice (8 weeks old) were injected s.c. at 2 sites, 
with 2 injections (100 µl) of emulsified Freund’s 
complete adjuvant containing 100 µg of Myelin 
proteolipid protein aa 139-151 (PLP139-151) and 200 
µg Mycobacterium tuberculosis H37Ra followed 2 
hours later with 200 ng Pertussis toxin (PTX; 
Hooke Laboratories, Lawrence, MA) injected i.p. 
The preparation and immunization of the synthetic 
cannabinoid R(+)WIN55,212-2 (Sigma) was 
modified from previous studies (30). 
R(+)WIN55,212-2 was prepared in Cremophor El 
(Sigma) and PBS (20:80) and administered (20 
mg/Kg) i.p. on days 0, 1, 2, 3, 4 and 5. Rabbit anti-
mouse IFN-β polyclonal antibody (Millipore, 
Cork, Ireland) was administered i.p. (2 x 103 
Neutralizing Units) on days 3 and 5 after PLP 
immunization. Control mice received 
Cremophor:PBS (20:80) as vehicle. Data are from 
4-8 mice per group. To ensure objective clinical 
scoring, all mice had electronic data chips placed 
s.c. prior to experiment and were subsequently 
tracked by barcode reader (AVID, UK). An 
investigator blinded to the treatment of the mice 
scored all animals by barcode number, to 
determine the mean clinical score as follows: 0, 
normal; 1, limp tail or hind limb weakness; 2, limp 
tail and hind limb weakness, 3, partial hind limb 
paralysis; 4, complete hind limb paralysis, and 5, 
moribund.   
 
Histology - Spinal cords were dissected and fixed 
in 10% formaldehyde saline. Spinal cords were 
sectioned and stained with haematoxylin and eosin 
for inflammatory scoring (31). Inflammatory 
scores were as follows: 0, no inflammatory cells; 
1, a few scattered inflammatory cells; 2, 
perivascular cuffing; 3, perivascular cuffing with 
extensions into adjacent parenchyma, or 
4 
 
parenchymal infiltration without obvious cuffing. 
Demyelination was assessed on Luxol fast blue-
stained spinal cord sections and scored as follows: 
0, no evident demyelination; 1, decreased 
myelination with no foci; 2, obvious 
demyelination with evident foci; 3: severe 
demyelination. An investigator blinded to the 
treatment groups scored all stained sections, with 
slides labeled by mouse barcode number. 
 
Western immunoblotting - Astrocytes were 
seeded in 6-well plates (2 × 105 cells/ml). Cells 
were treated with Poly(I:C) (25 µg/ml) for 5-360 
min or pre-treated with R(+)WIN55,212-2 (20 
µM) for 1 h prior to Poly(I:C) (25 µg/ml) exposure 
for 1 h. Cells were then washed in ice-cold PBS 
before being lysed on ice for 10 min in 150 µl lysis 
buffer (20mM HEPES, pH 7.4 containing 10mM 
KCl, 1.5mM MgCl2, 1mM EDTA, 1mM EGTA, 1 
mM dithiothreitol, 0.1mM PMSF, pepstatin A (5 
µg/ml), leupeptin (2 µg/ml), and aprotinin (2 
µg/ml)). Cell lysates were centrifuged at 13,000 X 
g for 15 min at 4°C. The supernatant was mixed 
with SDS-PAGE sample buffer (0.125 Tris-HCl 
pH 6.8, 20% (v/v) glycerol, 4% (w/v) SDS, 1.4 M 
β-mercaptoethanol and 0.0025% (w/v) 
bromophenol blue). For in vivo experiments 
samples of spinal cord were homogenised in lysis 
buffer and the resulting lysate centrifuged (16,000 
X g for 15 min at 40C). Supernatants were then 
further centrifuged (100,000 X g for 1 h at 40C) 
and the supernatant (cytosolic fraction) added to 
sample buffer. All samples in sample buffer were 
boiled for 10 min and separated on 10% SDS-
PAGE gels. Proteins were transferred to 
nitrocellulose membrane (Sigma) and blocked for 
1 h in 5% dried milk. Membranes were incubated 
overnight at 4°C with mouse monoclonal phospho-
IκB-α antibody (1:1,000 in 5% dried milk; Cell 
Signaling Technology Inc., Danvers, MA), rabbit 
monoclonal phospho-Ser-396 IRF3 antibody 
(1:750 in 2.5% BSA; Cell Signaling Technology 
Inc.), rabbit monoclonal total IRF3 antibody 
(1:1,000 in 2.5% BSA; Cell Signaling Technology 
Inc.) or mouse monoclonal IκB-α antibody (1:200 
in 5% dried milk; Santa Cruz Biotechnology, 
Santa Cruz, CA). Membranes were washed and 
incubated with anti-mouse or anti-rabbit IRDye 
Infrared secondary antibody (1:5,000 in 5% dried 
milk; Licor Biosciences, Lincoln, NE) for 1 h in 
the dark at room temperature. The membranes 
were then washed and immunoreactive bands were 
detected using Odyssey Infrared Imaging System 
(Licor Biosciences). Membranes were stripped and 
incubated with mouse monoclonal anti-β-actin 
antibody (1:10,000; overnight at 4oC, Sigma). 
Molecular weight markers were used to calculate 
molecular weights of proteins represented by 
immunoreactive bands. Densitometry was 
performed using ImageJ Software and values were 
normalized for protein loading relative to levels of 
β-actin or total IRF3. 
 
Preparation of nuclear and cytosolic fractions – 
Primary astrocytes were seeded in 6-well plates (2 
× 105 cells/ml). Cells were pre-treated with or 
without R(+)WIN55,212-2 (20 µM) for 1 h prior to 
stimulation in the absence or presence of Poly(I:C) 
(25 µg/ml; 1 h). Cells were then washed in ice-
cold PBS and scraped into 1ml of ice-cold 
hypotonic buffer (10mM HEPES-NaOH buffer, 
pH 7.9, containing 1.5mM MgCl2, 10mM KCl, 
0.5mM DTT, and 0.5mM PMSF). Cells were 
pelleted by centrifugation at 21,000 X g for 10 min 
and then lysed for 10 min on ice in hypotonic 
buffer (30 µl) containing 0.1% (v/v) Nonidet P-40. 
Lysates were centrifuged at 21,000 X g for 10 min. 
The resulting supernatants constituted cytosolic 
fractions and were measured for levels of IRF3 by 
Western immunoblotting. The pellets were 
resuspended in 20mM HEPES-NaOH buffer, pH 
7.9 (25 µl), containing 40mM NaCl, 1.5mM 
MgCl2, 0.2mM EDTA, 25% (w/v) glycerol, and 
0.5mM PMSF and incubated for 15 min on ice. 
Incubations were then centrifuged at 21,000 X g 
for 10 min, and the supernatants were removed 
into 10mM HEPES-NaOH buffer, pH 7.9 (30 µl), 
containing 50mM KCl, 0.2mM EDTA, 20% (w/v) 
glycerol, 0.5mM PMSF and 0.5mM DTT. Such 
samples constituted nuclear extracts and were 
assessed for levels of IRF3 by Western 
immunoblotting. 
 
ELISA Detection of TNF-α and IL-8 - U373-
CD14 cells (2 x 105 cells/ml), primary astrocytes 
(2 x 105 cells/ml) and human PBMCs (1 x 106 
cells/ml) were seeded in 96-, 12- and 24-well 
plates respectively. Cells were pre-treated with 
R(+)WIN55,212-2 (1-50 µM) for 1 h prior to LPS 
(100 ng/ml) or Poly(I:C) (25 µg/ml) exposure for 6 
h with the exception of PBMCs, which were pre-
treated with R(+)WIN55,212-2 (20 µM) and S(-
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)WIN55,212-2 (20 µM) for 1 h prior to Poly(I:C) 
(25 µg/ml) exposure for 3 h. Cell culture 
supernatants were assayed for levels of TNF-α and 
IL-8 by ELISA (Duoset, R&D Systems, 
Abingdon, UK). 
 
Quantitative RT-PCR - HEK293 cells, U373-
CD14 cells, BMDMs, primary astrocytes (all at 2 x 
105 cells/ml) and human PBMCs (1 x 106 cells/ml) 
were seeded on 12-well plates. Cells were pre-
treated with R(+)WIN55,212-2 or S(-)WIN55,212-
2 (1-50 µM) for 1 h prior to LPS (100 ng/ml) or 
Poly(I:C) (25 µg/ml) exposure for 4 h with the 
exception of PBMCs, which were pre-treated with 
R(+)WIN55,212-2 (20 µM) for 1 h prior to 
Poly(I:C) (25 µg/ml) exposure for 3 h, and 
BMDMs, which were pre-treated with 
R(+)WIN55,212-2 (20 µM) for 1 h prior to 
Poly(I:C) (25 µg/ml) exposure for 18 h. In some 
experiments cells were pre-treated with the CB1 
receptor antagonist SR141716 (N-[piperidin-1-yl]-
5-[4-chlorophenyl]-1-[2,4-dichlorophenyl]-4-
methyl-1-H-pyrazole-3-carboxamide], NIMH 
Chemical Synthesis Programme Batch 10937-163-
1; 1 µM), the CB2 receptor antagonist SR144528 
([N-[(1s)-endo-1,3,3-timethylbicyclo[2.2.1]heptan-
2-yl]5-(4-choro-3-methylpanyl)-1-(4-
methlbenzyl)pyrazole-3-carboxamide] Chemical 
Synthesis Programme: Batch No. 12687-177; 1 
µM) or PTX (100 ng/ml, Sigma) prior to 
R(+)WIN55,212-2 or S(-)WIN55,212-2 exposure. 
RNA was extracted from cells and spinal cord 
using Tri Reagent™ (Invitrogen, Dun Laoghaire, 
Ireland) and cDNA generated from normalized 
RNA using Superscript II reverse transcriptase. 
cDNA (1 µg) was amplified in the presence of 
SYBR® Green PCR mastermix (New Engand 
Biolabs; Ipswich, MA). Primers used were as 
follows: murine IFN-β: forward 5′-
GGAGATGACGGAGAAGATGC-3′ and reverse 
5′-CCCAGTGCTGGAGAAATTGT-3′; murine 
GFAP: forward 5′-
GATCGCCACCTACAGGAAAT-3′ and reverse 
5′-GTTTCTCGGATCTGGAGGTT-3′; murine 
CD11b: forward 5′-
CCTTGTTCTCTTTGATGCAG-3′ and reverse 5′-
GTGATGACAACTAGGATCTT-3′; human IFN-
β: forward 5′-
GACCAACAAGTGTCTCCTCCAAA-3 and 
reverse ′5′-CTCCTCAGGGATGTCAAAGTTCA-
3. As internal control murine GAPDH: forward 5′-
AGGTCATCCCAGAGCTGAACG-3′ and reverse 
5′- ACCCTGTTGCTGTAGCCGTA-3′ and human 
HPRT: forward 5′-
TTGCTGACCTGCTGGATTAC-3′ and reverse 
5′-TCTCCACCAATTACTTTTATGTCC-3′ were 
used in a similar reaction. Accumulation of gene-
specific PCR products was measured continuously 
by means of fluorescence detection over 40 cycles. 
Samples were run in duplicate as follows: 10 min 
at 95oC and for each cycle, 10 seconds at 95oC, 10 
seconds at 55oC and 1 min at 72oC. Gene 
expression was calculated relative to the 
endogenous control and analysis was performed 
using the 2-∆∆CT method.  
 
Screening of cannabinoid receptor expression - 
Total cellular RNA was prepared from HEK293 
cells, cDNA was generated as above and PCR 
amplification was performed to selectively amplify 
regions of CB1, CB2 and GAPDH cDNA.  
 
cAMP assay - HEK293 cells were pre-treated 
with or without PTX (100 ng/ml; 24 h), SR141716 
(SR1; 1 µM for 1 h) and SR144528 (SR2; 1 µM 
for 1 h) prior to treatment with the selective CB1 
agonist ACEA (100 nM for 1 h; Tocris Bioscience, 
Bristol, UK) or the selective CB2 agonist JWH133 
(100 nM for 1 h; Sigma). Cells were then 
incubated with the potent cAMP 
phosphodiesterase inhibitor, 3-isobutyl-1-
methylxanthine (500 µM for 15 min; Sigma) and 
stimulated with forskolin (30 µM for 30 min; 
Sigma) to induce cAMP. Lysates were harvested 
and assessed for levels of intracellular cAMP 
using a cAMP parameter kit as per manufacturer’s 
instructions (R&D Systems).  
 
Confocal microscopic analysis of IRF3 - For 
characterizaton of endogenous IRF3, primary 
astrocytes were seeded (1 x 105 cells/ml) in 4-well 
chamber slides (Lab-Tek; Roskilde, Denmark) and 
grown for 24 h. Cells were pre-treated with 
R(+)WIN55,212-2 (20 µM) or S(-)WIN55,212-2 
(20 µM) for 1 h prior to Poly(I:C) (25 µg/ml) 
exposure for 1 h. Cells were fixed in 4% 
paraformaldehyde, permeabilised with 0.2% Triton 
X-100 in PBS for 10 min at room temperature and 
blocked with 10% goat serum (Vector 
Laboratories; Peterborough, UK) for 2 h. Cells 
were treated overnight at 4°C with rabbit 
polyclonal IRF3 antibody (1:200 in 5% goat 
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serum; Santa Cruz Biotechnology). Cells were 
washed and incubated with goat anti-rabbit 
Alexa488 secondary antibody (1:500 in 5% goat 
serum; Invitrogen) and DAPI (1.5 µg/ml) in PBS, 
washed, and mounted (Vectashield; Vector 
Laboratories). All samples were viewed using an 
Olympus FluoView FV1000 confocal laser 
scanning microscope equipped with the 
appropriate filter sets. Acquired images were 
analysed using the Olympus FV-10 ASW imaging 
software. Negative control experiments were 
performed by replacing the primary antibody with 
isotype controls (Millipore) and using equal gain 
settings during acquisition and analysis. 
 
Statistical analysis - Data are expressed as means 
with SEM, and the results represent two or three 
independent experiments. Statistical comparisons 
of different treatments were done by a one-way 
ANOVA using a post hoc Student Newman Keuls 
test. Differences with a p value less than 0.05 were 
considered statistically significant. 
 
RESULTS 
 
R(+)WIN55,212-2 regulates TLR3/4 activation of 
NF-κB. We have shown that R(+)WIN55,212-2 
targets the IL-1-induced transactivation of NF-κB 
in astrocytes (24). Since TLRs and IL-1R share 
signaling components (25), we extended our 
previous study to determine if TLR signaling was 
sensitive to R(+)WIN55,212-2. TLR3 and TLR4 
were targeted given their involvement in EAE (26) 
and evidence that their expression is up-regulated 
in MS lesions (23). Initial experiments assessed 
the ability of R(+)WIN55,212-2 to regulate NF-κB 
activity induced by TLR3 in response to Poly(I:C) 
and by TLR4 in response to LPS in HEK293 cells. 
LPS and Poly(I:C) enhanced the expression of NF-
κB-regulated luciferase reporter gene whilst 
R(+)WIN55,212-2 dose-dependently abrogated 
TLR4 (Fig. 1A) and TLR3 (Fig. 1C) NF-κB 
induction. The enantiomeric form of 
R(+)WIN55,212-2, S(-)WIN55,212-2, failed to 
affect the ability of LPS (Fig. 1B) and Poly(I:C) 
(Fig. 1D) to activate NF-κB, suggesting a 
stereoselective mechanism underlies the effects of 
R(+)WIN55,212-2. 
 Given the role of astrocytes in MS, in 
addition to NF-κB involvement in astrocyte-
mediated neuroinflammation (32), we determined 
whether R(+)WIN55,212-2 could regulate TLR 
activation of NF-κB and the NF-κB responsive 
gene TNF-α in astrocytes. Using astrocytoma 
U373 cells we demonstrated that R(+)WIN55,212-
2 inhibited Poly(I:C)- and LPS-induced activation 
of NF-κB and expression of TNF-α (supplemental 
Fig. 1). As a more physiologically relevant 
approach primary astrocytes were employed, and 
the regulatory effects of R(+)WIN55,212-2 were 
confirmed in these cells with dose-dependent 
inhibition of LPS- and Poly(I:C)-induced TNF-α 
(Fig. 1E and G). Again, stereoselectivity for this 
effect was confirmed (Fig. 1F and H). 
 
R(+)WIN55,212-2 differentially regulates 
TLR3/4 induction of IRF3 and IFN-β. As 
MyD88 deficiency is protective in EAE (33), 
while TRIF deficiency exacerbates the disease 
(34), we next delineated the sensitivity of MyD88-
dependent and independent signaling to 
cannabinoid exposure. As the transcription factors 
IRF3 and IRF7 are activated by TLR3 and TLR4 
in a MyD88-independent manner that employs 
TRIF (19), the sensitivity of IRF3/IRF7 to 
R(+)WIN55,212-2 was evaluated. Exposure of 
HEK293-TLR4 cells to LPS enhanced expression 
of IRF3-regulated luciferase and this was 
abrogated in a dose-dependent manner by 
R(+)WIN55,212-2 (Fig. 2A). In contrast, 
R(+)WIN55,212-2, in a stereoselective manner, 
augmented Poly(I:C)-induced activation of IRF3 
in HEK293-TLR3 cells (Fig. 2B and C), indicating 
that R(+)WIN55,212-2 differentially regulates 
TLR3- and TLR4-induced activation of IRF3. The 
synergistic effects of Poly(I:C) and 
R(+)WIN55,212-2 were restricted to IRF3, since 
R(+)WIN55,212-2, in a stereoselective manner, 
inhibited LPS- (Fig. 2D) and Poly(I:C)-induced 
(Fig. 2E and F) IRF7-regulated luciferase. The 
selective augmentation by R(+)WIN55,212-2 of 
TLR-induced activation IRF3 is also apparent in 
astrocytoma cells (supplemental Fig.2). 
IRF3 is an important regulator of type I 
IFNs, including IFN-β (35). Since we 
demonstrated that R(+)WIN55,212-2 augments 
TLR3, but inhibits TLR4, activation of IRF3 (Fig. 
2A and B), we addressed the functional 
consequences of these effects of R(+)WIN55,212-
2 on TLR3/TLR4 activation of the IFN-β 
promoter. Poly(I:C) activated the IFN-β promoter 
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in HEK293-TLR3 (Fig. 2G) and U373-CD14 
astrocytoma (Fig. 2H) cells with R(+)WIN55,212-
2 potentiating this effect in both cell types. Such 
effects of R(+)WIN55,212-2 are mediated by 
targeting of the IRF-binding enhancer element of 
the IFN-β promoter (termed the positive regulatory 
domains (PRD)I-III) given that R(+)WIN55,212-2 
augmented Poly(I:C) induction of a reporter gene 
that is regulated exclusively by PRDI-III (Fig. 2I). 
We next examined the effects of R(+)WIN55,212-
2 on the expression of IFN-β mRNA in BMDMs. 
Exposure of BMDMs to R(+)WIN55,212-2 alone 
caused some modest induction of IFN-β mRNA 
with LPS and Poly(I:C) showing much stonger 
levels of induction (Fig. 2J, K). Interestingly 
R(+)WIN55,212-2 reduced LPS (Fig. 2J), but 
enhanced Poly(I:C) (Fig. 2K) induction of IFN-β 
mRNA. Similarly, exposure of primary astrocytes 
to R(+)WIN55,212-2 enhanced, in a 
stereoselective manner, Poly(I:C)-induced 
expression of IFN-β mRNA (supplemental Fig. 3A 
and B). 
  
R(+)WIN55,212-2 augments TLR3-induced IRF3 
activation and IFN-β induction in a cannabinoid 
receptor-independent manner. We next 
characterized the cannabinoid pharmacology 
underlying the above effects. Receptor expression 
was first confirmed on HEK293 cells (Fig. 3A) and 
receptor involvement was addressed using the CB1 
and CB2 antagonists, SR141716 and SR144528, 
respectively. Pre-exposure to SR141716 (Fig. 3B 
and C) or SR144528 (Fig. 3D and E), failed to 
attenuate the ability of R(+)WIN55,212-2 to 
potentiate Poly(I:C)-induced activation of IRF3 
(Fig. 3B, D) and expression of IFN-β mRNA (Fig. 
3C and E). This indicates that R(+)WIN55,212-2 
impacts the TLR3-IRF3-IFN-β axis independently 
of CB1/2. Since CB1/2 receptors signal via Gi 
proteins, we employed the Gi inhibitor PTX to 
validate this finding. PTX had no effect on the 
stimulatory effect of R(+)WIN55,212-2 on 
Poly(I:C)-induced activation of IRF3 (Fig. 3F) and 
expression of IFN-β (Fig. 3G), confirming that 
R(+)WIN55,212-2 is acting in a cannabinoid 
receptor-independent manner. Both CB1 and CB2 
antagonists and PTX were active in our system as 
they prevented the inhibitory effects of specific 
CB1 and CB2 agonists on forskolin-induced cAMP 
production (Fig. 3H). 
 
The TLR3-TRIF-IRF3 signaling axis is a target 
for R(+)WIN55,212-2. We next defined the 
molecular target for R(+)WIN55,212-2 in the 
TLR3 pathway. TRIF was a primary target since it 
is a receptor proximal adaptor for TLR3 (36) and 
TRIF is protective in EAE (34). Overexpression of 
TRIF in HEK293 cells increased IRF3 luciferase 
activity (Fig. 4A); this was dose-dependently 
augmented by R(+)WIN55,212-2 (Fig. 4A) 
suggesting that TRIF-induced signaling is 
positively regulated by R(+)WIN55,212-2. TRIF-
deficient cells were used to evaluate the 
importance of TRIF for manifesting the effects of 
R(+)WIN55,212-2 on IFN-β. The responsiveness 
to Poly(I:C) is greatly reduced in TRIF-deficient 
BMDMs with only modest induction of IFN-β in 
response to Poly(I:C) observed (Fig. 4B). 
Interestingly, R(+)WIN55,212-2 failed to 
modulate this effect (Fig. 4B), further suggesting 
that R(+)WIN55,212-2 targets a TRIF-mediated 
pathway.  
We next investigated if R(+)WIN55,212-2 
directly targets IRF3. The phosphorylation of IRF3 
is required for its dimerization and nuclear 
translocation (37). Poly(I:C) induced the time-
dependent phosphorylation of IRF3 in primary 
astrocytes (Fig. 4C) and R(+)WIN55,212-2 failed 
to modulate this phosphorylation (Fig. 4D). We 
next assessed the effects of R(+)WIN55,212-2 on 
subcellular localization of IRF3. IRF3 localizes 
predominantly to the cytoplasm, while Poly(I:C) 
stimulation induces its nuclear translocation (Fig. 
4E, F). Intriguingly, R(+)WIN55,212-2 promoted 
nuclear localization of IRF3 in the presence and 
absence of Poly(I:C) (Fig. 4E, F) whilst the 
inactive enantiomer S(-)WIN55,212-2 is without 
effect (Fig. 4E). This effect was also confirmed in 
HEK293 cells by demonstrating that 
R(+)WIN55,212-2 promotes the nuclear 
translocation of IRF3-GFP fusion protein 
(supplemental Fig. 4). The positive effects of 
R(+)WIN55,212-2 on the nuclear localization of 
IRF3 provides a plausible mechanistic basis to the 
enhancement of TLR3-TRIF-IRF3-IFN-β 
pathway. 
 
R(+)WIN55,212-2 manifests protective effects in 
EAE in an IFN-β-dependent manner. Given the 
therapeutic effects of IFN-β in MS treatment it 
8 
 
was attractive to speculate that R(+)WIN55,212-2 
exerts its therapeutic properties in animal MS 
models by inducing endogenous IFN-β (26). A 
relapsing mouse model of EAE involving 
immunization with PLP139-151 (PLP) was employed 
to address this hypothesis. PLP-immunized mice 
develop clinical symptoms of disease from day 5 
post-immunization, with disease severity peaking 
on day 16 followed by a relapse on day 26 (Fig. 
5A). Mice treated with R(+)WIN55,212-2 showed 
delayed development of EAE and attenuated 
disease severity (Fig. 5A). However, PLP-
immunized mice treated with R(+)WIN55,212-2 
and an anti-IFN-β antibody were not protected 
(Fig. 5A). Scoring of histology sections confirmed 
R(+)WIN55,212-2 reduced lymphocytic 
infiltration (Fig. 5B and C) and demyelination of 
spinal cords (Fig. 5D). However, anti-IFN-β 
ablated these protective effects (Fig. 5B, C and D). 
Animals that received anti-IFN-β antibody-alone 
displayed a similar degree of inflammation (Fig. 
5C) and demyelination (Fig. 5D) as vehicle-treated 
mice.  
We also characterized the effects of 
R(+)WIN55,212-2 on astrogliosis/microglial 
activation in PLP-immunized mice. 
R(+)WIN55,212-2 attenuated both GFAP mRNA 
(Fig. 5E) and CD11b mRNA (Fig. 5F) in EAE 
spinal cord, and this was reversed by anti-IFN-β. 
Finally, to characterize the anti-inflammatory 
effects of R(+)WIN55,212-2 at the molecular 
level, IκB proteins in spinal cords were analyzed. 
IκB proteins regulate NF-κB by sequestering NF-
κB in the cytoplasm (38) with NF-κB activation 
dependent on phosphorylation and degradation of 
IκB. R(+)WIN55,212-2 reduced IκB-α 
phosphorylation and IκB-α degradation associated 
with EAE, and these effects were reversed by anti-
IFN-β (Fig. 5G). This provides strong evidence 
that IFN-β plays a role in the protective effects of 
R(+)WIN55,212-2 in EAE.  
 
Effect of R(+)WIN55,212-2 on IFN-β expression 
in human PBMCs. Since R(+)WIN55,212-2 
augments IFN-β and its protective effects in EAE 
are IFN-β-dependent, we determined if 
R(+)WIN55,212-2 modulated IFN-β production in 
cells from MS patients. Indeed a defect in IFN-β 
production has been reported in immune cells from 
MS patients (39). PBMCs isolated from healthy 
subjects were responsive to Poly(I:C) with an 
increase in IFN-β mRNA observed, while 
R(+)WIN55,212-2 ablated this (Fig. 6A). In 
contrast, PBMCs isolated from MS subjects were 
unresponsive to Poly(I:C) with no IFN-β mRNA 
detected (Fig. 6B). Remarkably, cells from MS 
subjects displayed sensitivity to R(+)WIN55,212-
2, with R(+)WIN55,212-2 robustly inducing IFN-β 
mRNA in the absence of Poly(I:C) (Fig. 6B). 
Again, the enantiomeric form of R(+)WIN55,212-
2, S(-)WIN55,212-2, had no effect on IFN-β 
expression profile in healthy (Fig. 6C) and MS 
patient (Fig. 6D) cells. These findings are 
significant given that plasmacytoid dendritic cells 
from MS patients produce lower levels of type I 
IFN (40) and are weakly responsive to IFN-β-
induced maturation (41). The differential 
sensitivity of cells from healthy and MS subjects 
appear to be specific for IFN-β, since 
R(+)WIN55,212-2 blocks Poly(I:C)-induced 
expression of TNF-α and IL-8 in PBMCs from 
both healthy (Fig. 6E and G) and MS (Fig. 6F and 
H) subjects. It is worth noting that paradoxically 
the R(+)WIN55,212-2-induced expression of IFN-
β in MS cells is inhibited by Poly(I:C), suggesting 
that TLR3 stimulation of MS cells drives a 
desensitizing signal. The induction of IFN-β 
mRNA in cells from MS patients by 
R(+)WIN55,212-2, coupled to the central role of 
IFN-β in mediating the protective effects of 
R(+)WIN55,212-2 in EAE, identifies a regulatory 
pathway that may be a valuable target in the 
design of new therapeutics to treat MS. 
 
DISCUSSION 
 
 Here we aimed to understand the molecular 
mechanisms of the immunomodulatory effects of 
the cannabinoid R(+)WIN55,212-2 and in so doing 
we have identified an important regulatory 
pathway that may be able to control pathogenesis 
in MS. We propose that R(+)WIN55,212-2 
controls the expression of IFN-β. In addition to 
ameliorating pro-inflammatory signaling induced 
by TLR3/4, R(+)WIN55,212-2 augments TLR3 
signaling, enhancing IFN-β expression that 
ameliorates the pathology associated with EAE. 
We also demonstrate that cells from MS patients 
are especially sensitive to R(+)WIN55,212-2 in 
terms of increased expression of endogenous IFN-
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β and this strongly indicates the mechanism 
described has relevance to treatment of MS. 
 The study highlights the anti-inflammatory 
potential of R(+)WIN55,212-2 by virtue of its 
inhibitory effects on the NF-κB pathway. We have 
previously shown that R(+)WIN55,212-2 blocks 
the IL-1 pathway leading to NF-κB (24) and here 
we demonstrate for the first time that it can inhibit 
TLR3/4-induced activation of NF-κB. This likely 
makes a major contribution to the inhibitory 
effects of R(+)WIN55,212-2 on pro-inflammatory 
gene expression. Indeed, we demonstrate that 
R(+)WIN55,212-2 blunts TLR3/4 induction of 
TNF-α. Such effects translate into strong anti-
inflammatory activity in vivo. Thus 
R(+)WIN55,212-2 blunts neutrophil migration in a 
mouse peritonitis model (42) while 
R(+)WIN55,212-2 abrogates the clinical 
development of EAE (30). The inhibitory effects 
of R(+)WIN55,212-2 on leukocyte adhesion to 
endothelia is likely to contribute to its therapeutic 
properties in EAE (43). However whilst these 
direct anti-inflammatory effects of 
R(+)WIN55,212-2 are pivotal, the present study 
highlights a novel mechanistic basis to its 
protective effects by virtue of its ability to induce 
endogenous IFN-β.  
 We provide evidence for the first time that 
IRF3 is a target for synthetic cannabinoids. We 
propose that R(+)WIN55,212-2 can enhance IRF3 
nuclear localization and positively impact on IFN-
β expression in response to TLR3 signaling. 
Intriguingly, R(+)WIN55,212-2 exerts differential 
effects on LPS- and Poly(I:C)-induced activation 
of IRF3 and expression of IFN-β. The mechanistic 
basis to this remains to be delineated. However it 
has recently been shown that the TIR adaptor Mal, 
that is employed by TLR4 but not TLR3, can 
negatively regulate the induction of IFNβ (44) and 
it is interesting to speculate that Mal may mask 
any positive effects of R(+)WIN55,212-2 on TLR4 
signaling. Furthermore, TLR3 signaling to NF-κB 
and IRF3 is differentially sensitive to 
R(+)WIN55,212-2 suggesting that the latter targets 
a component of the IRF pathway not common to 
the NF-κB pathway. Data presented herein suggest 
that R(+)WIN55,212-2 targets IRF3 and promotes 
its nuclear localization. It should be noted that the 
increased nuclear localization of IRF3 in response 
to R(+)WIN55,212-2 may reflect increased nuclear 
translocation and/or nuclear sequestration of IRF3. 
Indeed it is plausible that R(+)WIN55,212-2  may 
have a nuclear target that sequesters IRF3 and it is 
especially interesting to note that cannabinoids 
have previously been shown to be capable of 
targeting the nuclear peroxisome proliferators-
activated receptors (PPARs) (45). Indeed a nuclear 
target for R(+)WIN55,212-2 may potentially 
explain why it positively regulates IRF3 in 
response to Poly(I:C) and yet inhibits IRF7 
activation in response to the same stimulus. Given 
that IRF3 and IRF7 tend to share the same 
upstream regulators the differential sensitivity of 
these two transcription factors to R(+)WIN55,212-
2 suggest that IRF3 may itself be targeted by 
R(+)WIN55,212-2 and its effector molecules 
leading to increased nuclear localization whereas 
IRF7 is not targeted by this process but instead is 
subject to another form of regulation that results in 
its inhibition. Indeed the NF-κB pathway is also 
subject to negative regulation by R(+)WIN55,212-
2 and we have previously provided evidence that it 
targets the transactivation capacity of NF-κB (24). 
R(+)WIN55,212-2 may similarly regulate the 
transactivation potential of IRF7 and this is 
consistent with the presently described inhibitory 
effects of R(+)WIN55,212-2 on the transactivating 
ability of the Gal4-IRF7 fusion protein.  
 The concentrations of R(+)WIN55,212-2 
used are in line with those used in various anti-
inflammatory paradigms in vitro (46-48). 
Furthermore, the dose (30,49,50) and route of 
administration (30,43,49) for our in vivo 
experiments are comparable with the therapeutic 
doses used in these animal studies. The effects of 
R(+)WIN55,212-2 can not be explained by mere 
virtue of its lipophilic characteristics since its 
enantiomeric form S(-)WIN55,212-2 is ineffective 
in our studies. R(+)WIN55,212-2 binds to both 
CB1 and CB2, however, use of selective CB1/2 
antagonists and PTX failed to inhibit the effect of 
R(+)WIN55,212-2 on IRF3 and IFN-β, suggesting 
that R(+)WIN55,212-2 is acting in a cannabinoid 
receptor-independent manner. Indeed, both CB1- 
(24) and CB2- (46) independent effects of 
R(+)WIN55,212-2 have been demonstrated, which 
further suggests the existence of additional 
cannabinoid receptors with some evidence that 
cannabinoids may act on PPARs (45). Furthermore 
the inability of the enantiomeric form of 
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R(+)WIN55,212-2 to mimic its effects argues for a 
stereoselective receptor-mediated process(es).  
 This study highlights the importance of 
IFN-β production as a mechanism underlying the 
protective effects of R(+)WIN55,212-2 in EAE. 
We propose that such effects are due to a 
combination of neuroprotection and dampening of 
inflammation. Whilst it is clear that the anti-
inflammatory properties of R(+)WIN55,212-2 may 
be manifested directly by its effects on NF-κB, it 
is also apparent that the in vivo anti-inflammatory 
effects of R(+)WIN55,212-2 are dependent on 
IFN-β and the immunomodulatory potential of the 
latter. Such directly- and indirectly-acting 
mechanisms of R(+)WIN55,212-2 may combine to 
explain its strong anti-inflammatory propensity.  
 Our studies also probed the effects of 
R(+)WIN55,212-2 on IFN-β in PBMCs and the 
findings raise intriguing issues. PBMCs from 
healthy donors responded to TLR3 stimulation by 
enhancing IFN-β production. Interestingly, this 
was absent in MS patient PBMCs, suggesting that 
the TLR3 pathway may be desensitized, at least 
with respect to IFN-β induction. Indeed viral 
involvement in MS manifestation has been 
demonstrated (51), and it is interesting to speculate 
that MS patients may be pre-sensitized to viral 
infection showing some form of TLR3 tolerance. 
Intriguingly, the non-responsiveness of MS patient 
PBMCs to Poly(I:C) is only relevant in the context 
of IFN-β induction since Poly(I:C) shows 
comparable efficacy in inducing TNF-α and IL-8 
in cells from healthy and MS patients. Thus any 
form of TLR3 tolerance that may exist appears to 
be restricted to the pathway leading to IFN-β and 
this may explain why exogenous administration of 
IFN-β is effective in the treatment of MS. 
Remarkably, R(+)WIN55,212-2 alone induced the 
expression of IFN-β in PBMCs from MS patients. 
Thus whatever the basis underlying the refractory 
nature of MS cells to TLR3-induced IFN-β 
expression, R(+)WIN55,212-2 can bypass this 
blockage. This argues strongly in favor of the 
therapeutic potential of R(+)WIN55,212-2 in MS 
and presents an additional novel therapeutic 
strategy to the current exogenous administration of 
IFN-β. Intriguingly the induction of IFN-β by 
R(+)WIN55,212-2 in PBMCs from MS patient is 
strongly inhibited by Poly(I:C). This suggests that 
the stimulation of TLR3 in cells from MS patients 
generates a negative input on IFN-β expression 
and is consistent with suggestions that viral 
infection can exacerbate disease.  
Whilst cannabinoids show promising 
therapeutic effects in EAE models and MS 
patients, their mechanism(s) of action are poorly 
understood. We present a novel insight into the 
molecular basis underlying their therapeutic 
properties. We suggest that the innate arm of the 
immune response is a target for cannabinoid anti-
inflammatory action and highlight a novel dual 
mechanism of action of R(+)WIN55,212-2. Firstly, 
it can exert anti-inflammatory properties by 
downregulating TLR-induced activation of NF-κB 
and induction of pro-inflammatory mediators. In 
parallel, by enhancing activation of IRF3 and 
induction of IFN-β it can boost an endogenous 
protective system. Such effects of 
R(+)WIN55,212-2, in particular its capacity to 
induce endogenous IFN-β, offers an attractive 
additional option to the current use of exogenously 
administered IFN-β.  
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FIGURE LEGENDS 
 
FIGURE 1. R(+)WIN55,212-2 negatively regulates TLR3/4-induced activation of NF-κB and 
expression of TNF-α. (A, B) HEK293-TLR4 and (C, D) HEK293-TLR3 cells were cotransfected with 
plasmids encoding NF-κB-regulated firefly luciferase (80 ng) and constitutively expressed TK Renilla 
luciferase (20 ng). 24 h post-transfection cells were treated in the absence or presence of (A) 
R(+)WIN55,212-2 (5-50 µM) and (B) S(-)WIN55,212-2 (5-50 µM) for 1 h prior to treatment with (A, B) 
LPS (100 ng/ml) and (C, D) Poly(I:C) (25 µg/ml) for 6 h. Cell lysates were assayed for firefly luciferase 
activity and normalised for transfection efficiency using Renilla luciferase activity. Data are presented 
relative to vehicle-treated cells and represent the mean ± S.E.M. of triplicate determinations from three 
independent experiments. (E-H) Primary mouse astrocytes were seeded into 12-well plates, pre-treated 
with (E, G) R(+)WIN55,212-2 (5-50 µM) or (F, H) S(-)WIN55,212-2 (5-50 µM) for 1 h and stimulated 
with (E, F) LPS (100 ng/ml) or Poly(I:C) (25 µg/ml) for 6 h. Supernatants were analysed for TNF-α 
production using sandwich ELISA. Data are presented as the mean ± S.E.M. of triplicate determinations 
from six animals and are representative of two independent experiments. *p < 0.05, **p < 0.01 and ***p 
< 0.001 compared with vehicle-treated cells. +++p < 0.001 compared with LPS- or Poly(I:C)-treated cells.  
 
FIGURE 2. R(+)WIN55,212-2 augments TLR3-induced activation of IRF3 and expression of IFN-β.  
(A) HEK293-TLR4 and (B, C) HEK293-TLR3 cells were cotransfected with pFA-IRF3 (30 ng) and pFR-
regulated firefly luciferase (60 ng) and constitutively expressed TK Renilla luciferase (20 ng). 
Transfected cells were left overnight and then cells were treated in the absence or presence of (A, B) 
R(+)WIN55,212-2 (5-50 µM) and (C) S(-)WIN55,212-2 (5-50 µM) for 1 h prior to treatment with/without 
(A) LPS (100 ng/ml) or (B, D) Poly(I:C) (25 µg/ml) for 6 h. (D) HEK293-TLR4 and (E, F) HEK293-
TLR3 cells were cotransfected with pFA-IRF7 (25 ng) and pFR-regulated firefly luciferase (60 ng), left 
overnight and treated in the absence or presence of (D, E) R(+)WIN55,212-2 (5-50 µM) and (F) S(-
)WIN55,212-2 (5-50 µM) for 1 h prior to treatment with with (D) LPS (100 ng/ml) or (E, F) Poly(I:C) (25 
µg/ml) for 6 h. (G, I) HEK293-TLR3 and (H) U373-CD14 cells were cotransfected with (G, H) IFN-β 
promoter or (I) PRDI-III-regulated firefly luciferase (80 ng) and constitutively expressed TK Renilla 
luciferase (20 ng), left overnight and treated in the absence or presence of R(+)WIN55,212-2 (1-50 µM) 
for 1 h prior to treatment with Poly(I:C) (25 µg/ml) for 6 h. In all cases (A-I) cell lysates were assayed for 
firefly luciferase activity and normalised for transfection efficiency using Renilla luciferase activity and 
represent the mean ± S.E.M. of triplicate determinations from three independent experiments. (J, K) 
BMDMs were treated in the absence or presence of R(+)WIN55,212-2 (5-50 µM) for 1 h prior to 
treatment with (J)  LPS (100 ng/ml) or (K) Poly(I:C) (25 µg/ml) for 18 h. cDNA was generated and 
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assayed by quantitative real time PCR for levels of IFN-β mRNA. The expression level of IFN-β was 
normalised relative to expression of the housekeeping gene GAPDH and represent the mean ± S.E.M. of 
triplicate determinations from three independent experiments. *p < 0.05, **p < 0.01 and ***p < 0.001 
compared with vehicle-treated cells. +p < 0.05, ++p < 0.01 and +++p < 0.001 compared with LPS- or 
Poly(I:C)-treated cells.  
 
FIGURE 3. R(+)WIN55,212-2 regulates TLR3 signaling in a cannabinoid receptor-independent 
manner. (A) Total cellular RNA was prepared from HEK293 cells and subjected to first strand cDNA 
synthesis using Superscript II reverse transcriptase and random oligonucleotide primers. PCR 
amplification was performed using TaqDNA polymerase and primers to selectively amplify regions of 
CB1, CB2 and GAPDH cDNA. (B, D, F) HEK293-TLR3 cells were cotransfected with pFA-IRF3 (30 ng) 
and pFR-regulated firefly luciferase (60 ng) and constitutively expressed TK Renilla luciferase (20 ng). 
Transfected cells were left overnight and then cells were pre-treated (1 h) with the inhibitors (B) 
SR141716 (1 µM), (D) SR144528 (1 µM) and (F) PTX (50 ng/ml) prior to exposure to R(+)WIN55,212-2 
(20 µM; 1 h), and then stimulated with Poly(I:C) (25 µg/ml) for 6 h. Cell lysates were assayed for firefly 
luciferase activity and normalised for transfection efficiency using Renilla luciferase activity. (C, E, G) 
HEK293-TLR3 cells were pre-treated (1 h) with the inhibitors (C) SR141716 (1 µM), (E) SR144528 (1 
µM) and (G) PTX (50 ng/ml) prior to exposure to R(+)WIN55,212-2 (20 µM; 1 h), and then stimulated 
with Poly(I:C) (25 µg/ml) for 4 h. cDNA was generated and assayed by quantitative real time PCR for 
levels of IFN-β mRNA. The expression level of IFN-β was normalised relative to expression of the 
housekeeping gene GAPDH. (H) HEK293 cells were pre-treated with or without PTX (100 ng/ml; 24 h), 
SR141716 (SR1; 1 µM for 1 h) and SR144528 (SR2; 1 µM for 1 h) prior to treatment with ACEA (100 
nM for 1 h) or JWH133 (100 nM for 1 h). Cells were then incubated with 3-isobutyl-1-methylxanthine 
(500 µM for 15 min) and stimulated with forskolin (30 µM for 30 min). Lysates were harvested and 
assessed for levels of intracellular cAMP using a cAMP parameter kit. Data represent the mean ± S.E.M. 
of triplicate determinations from three independent experiments. *p < 0.05, **p < 0.01 and ***p < 0.001 
compared with vehicle-treated cells. +p < 0.05 and ++p < 0.01 compared with (B-G) Poly(I:C)-treated cells 
and (H) forskolin-treated cells. $$p < 0.01 compared to cells treated with ACEA/JWH133 in the presence 
of forskolin. 
 
FIGURE 4. R(+)WIN55,212-2 augments the TLR3/TRIF/TBK1 signaling axis and promotes 
nuclear localization of IRF3. (A) HEK293-TLR3 cells were cotransfected with pFA-IRF3 (30 ng), pFR-
regulated firefly luciferase (60 ng), TRIF reporter constructs (50 ng) and constitutively expressed TK 
Renilla luciferase (20 ng). Transfected cells were left overnight and treated in the absence or presence of 
R(+)WIN55,212-2 (5-50 µM) for 6 h. Cell lysates were assayed for firefly luciferase activity and 
normalised for transfection efficiency using Renilla luciferase activity. Data are presented relative to 
vehicle-treated cells and represent the mean ± S.E.M. of triplicate determinations from three independent 
experiments. (B) TRIF deficient BMDMs were pre-treated (1 h) with R(+)WIN55,212-2 (20 µM) and 
then stimulated with Poly(I:C) (25 µg/ml) for 18 h. cDNA was generated and assayed by quantitative real 
time PCR for levels of IFN-β mRNA. The expression level of IFN-β was normalised relative to 
expression of the housekeeping gene GAPDH and represent the mean ± S.E.M. of triplicate 
determinations from three independent experiments. (C, D) Primary mouse astrocytes were seeded into 6-
well plates and treated with (C) Poly(I:C) (25 µg/ml) for various time points (5-360 min) or  pre-treated 
with (D) R(+)WIN55,212-2 (20 µM; 1 h) prior to stimulation with Poly(I:C) (25 µg/ml) for 1 h. Cell 
lysates were subsequently subjected to Western immunoblotting using  anti-phospho-Ser-396 IRF3, anti-
total IRF3 and anti-β-actin antibodies (lower panels). All immunoblots were subjected to densitometric 
analysis with levels of phospho-IRF3 normalized to total levels of IRF3 (upper panels). Densitometic data 
are representative of 8 (C) and 6 (D) independent experiments. *p < 0.05, **p < 0.01 and ***p < 0.001 
versus (A) non-transfected and (C, D) vehicle-treated cells.  +p < 0.05 and +++p < 0.001 compared with 
vehicle treated TRIF transfected cells. (E, F) Primary mouse astrocytes were grown  in chamber slides 
and pre-treated (1 h) with (E) R(+)WIN55,212-2 (20 µM) or (F) S(-)WIN55,212-2 (20 µM) for 1 h prior 
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to Poly(I:C) (25 µg/ml) exposure for 1 h. Cells were fixed, mounted in anti fade medium with DAPI and 
visualised using confocal microscopy. Confocal images were captured using a UV Zeiss 510 Meta 
System laser scanning microscope equipped with the appropriate filter sets. Data analysis was performed 
using the LSM 5 browser imaging software. Images are representative of three independent experiments. 
Scale bars are 20 µm. (F) Primary astrocytes were pre-treated with or without R(+)WIN55,212-2 (20 µM) 
for 1 h prior to stimulation in the absence or presence of Poly(I:C) (25 µg/ml; 1 h). Cytosolic and nuclear 
fractions were prepared and subsequently subjected to Western immunoblotting using anti-total IRF3 and 
anti-β-actin antibodies. Blots are representative of data obtained from 6 animals.  
 
FIGURE 5. Protective effects of R(+)WIN55,212-2 in EAE are mediated by IFN-β. (A) PLP-
immunized mice develop clinical symptoms of EAE from day 5 post-immunization, with disease severity 
peaking on day 16 followed by a relapse on day 26. Mice treated with R(+)WIN55,212-2 (administered 
(20 mg/Kg) intraperitoneally on days 0, 1, 2, 3, 4 and 5 after immunization) showed delayed development 
of EAE and attenuated disease severity. PLP-immunized mice treated with R(+)WIN55,212-2 and an anti-
IFN-β antibody (administered intraperitoneally (2 x 103 Neutralizing Units) on days 3 and 5 after PLP 
immunization) were not protected. (B) Representative images of Luxol fast blue-stained spinal cord 
sections from untreated mice, PLP-treated, PLP+WIN-treated and PLP+WIN+αIFNβ-treated mice 
illustrating the extent of demyelination and lymphocytic inflammation. The posterior funiculi of the spinal 
cord were observed under high power (right panels). Images are representative of data from 4-8 animals 
per treatment group. Scale bars are 200 µm and 50 µm. Spinal cords were sectioned and stained with 
haematoxylin and eosin and quantified for (C) spinal cord inflammation and (D) extent of demyelination 
using Luxol fast blue-stained spinal cord sections in treated groups. cDNA was generated from spinal 
cords and assayed by quantitative real time PCR for relative levels of (E) GFAP mRNA and (F) CD11b 
mRNA from vehicle-treated, PLP-treated, PLP+WIN-treated and PLP+WIN+αIFNβ-treated mice. The 
expression level of GFAP and CD11b was normalised relative to expression of the housekeeping gene 
GAPDH and represent the mean ± S.E.M. of triplicate determinations from 4-8 animals per treatment 
group. Cytosolic fractions were prepared from the spinal cord of vehicle-treated, PLP-treated, PLP+WIN-
treated and PLP+WIN+αIFNβ-treated mice. Cell lysates were subsequently subjected to Western 
immunoblotting using  anti-phospho Iκb-α, anti-total Iκb-α and anti-β-Actin antibodies. Blots are 
representative of data from 4-8 animals per treatment group. *p < 0.05, **p < 0.01 and ***p < 0.001 for 
differences between WIN-treated mice and other groups.  
 
FIGURE 6. R(+)WIN55,212-2 induces IFN-β expression in PBMCs from MS subjects. (A-F) PBMCs 
prepared from (A, C, E, G) healthy subjects and (B, D, F, H) MS patients were seeded into 24-well plates, 
pre-treated with R(+)WIN55,212-2 or S(-)WIN55,212-2  (5-50 µM) for 1 h and stimulated with Poly(I:C) 
(25 µg/ml) for 3 h. (A-D) cDNA was generated and assayed by quantitative real time PCR for relative 
levels of IFN-β mRNA. The expression level of IFN-β was normalised relative to expression of the 
housekeeping gene GAPDH and represent the mean ± S.E.M. of triplicate determinations from three 
patients. Supernatants were analysed for (E, F) TNF-α and IL-8 (G, H) production using sandwich 
ELISA. Data are presented as the mean ± S.E.M. of triplicate determinations from three patients. *p < 
0.05, **p < 0.01 and ***p < 0.001 compared with vehicle-treated cells (A, C, E, F, G and H) or cells 
treated with R(+)WIN55,212-2 in the presence of Poly(I:C) (B). ++p < 0.01 and +++p < 0.001 compared 
with Poly(I:C)-treated cells.  
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